127 related articles for article (PubMed ID: 36187555)
1. Genomic alterations predictive of poor clinical outcomes in pan-cancer.
Seldon CS; Meiyappan K; Hoffman H; Guo JA; Goel N; Hwang WL; Nguyen PL; Mahal BA; Alshalalfa M
Oncotarget; 2022; 13():1069-1077. PubMed ID: 36187555
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.
Deng C; Li ZX; Xie CJ; Zhang QL; Hu BS; Wang MD; Mei J; Yang C; Zhong Z; Wang KW
Hum Genomics; 2024 May; 18(1):55. PubMed ID: 38822443
[TBL] [Abstract][Full Text] [Related]
3. Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.
Alshalalfa M; Goglia AG; Swami N; Nguyen B; Hougen HY; Khan A; Kishan AU; Punnen S; Nguyen PL; Mahal BA; Dee EC
Urol Oncol; 2023 May; 41(5):253.e21-253.e26. PubMed ID: 37003878
[TBL] [Abstract][Full Text] [Related]
4. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
5. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract][Full Text] [Related]
6. A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.
Bui NQ; Przybyl J; Trabucco SE; Frampton G; Hastie T; van de Rijn M; Ganjoo KN
Clin Sarcoma Res; 2019; 9():12. PubMed ID: 31528332
[TBL] [Abstract][Full Text] [Related]
7. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract][Full Text] [Related]
8. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
[TBL] [Abstract][Full Text] [Related]
9. The
Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of
Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
[TBL] [Abstract][Full Text] [Related]
11. Characterizing genomic differences of human cancer stratified by the TP53 mutation status.
Wang M; Yang C; Zhang X; Li X
Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
14. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
15. KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
Saglam O; Tang Z; Tang G; Medeiros LJ; Toruner GA
PLoS One; 2020; 15(9):e0238477. PubMed ID: 32877461
[TBL] [Abstract][Full Text] [Related]
16. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.
Cheng Y; Ma L; Liu Y; Zhu J; Xin Y; Liu X; Wang Y; Zhang T; Yang C; Wang S; Cui H; Zhang L; Dai J; Shao L; Lin J; Ye J; Liu H
Lung Cancer; 2020 Jul; 145():63-70. PubMed ID: 32408134
[TBL] [Abstract][Full Text] [Related]
18. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
19. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
[TBL] [Abstract][Full Text] [Related]
20. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.
Schwaederle M; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Cell Cycle; 2015; 14(11):1730-7. PubMed ID: 25928476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]